Anti-human interleukin 36 receptor monoclonal antibody and liquid preparation
By adding appropriate viscosity regulators to the anti-human IL-36R monoclonal antibody liquid preparation, the viscosity of high-concentration antibodies is reduced, the viscosity problem of high-concentration antibodies is solved when injection of high-concentration antibodies is achieved, and high concentrations of low viscosity are achieved Liquid preparation, suitable for subcutaneous injection.
Patent Information
- Application Number
- CN202311302875.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-19
- Filing Date
- 2023-10-09
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-10-09
AI Technical Summary
The existing anti-human IL-36R monoclonal antibody drugs have increased viscosity at high concentrations, which makes it difficult to push the push rod during subcutaneous injection and cannot be effectively injected. The formula needs to be adjusted to obtain a high-concentration liquid preparation with low viscosity.
By adding appropriate viscosity regulators to the anti-human IL-36R monoclonal antibody liquid preparation, such as arginine hydrochloride, sodium chloride, sucrose, sorbitol, etc., combined with buffer salts, the viscosity of the antibody is reduced and it can be achieved at a high concentration. The viscosity under conditions is less than 10 cP, which is suitable for subcutaneous injection.
The low viscosity of high-concentration antibody liquid preparation is achieved, which ensures the feasibility of the push rod of the syringe, is suitable for subcutaneous injections, and improves the convenience and stability of the drug.
Smart Images

Figure BDA0004485739810000031 
Figure BDA0004485739810000032 
Figure BDA0004485739810000111
Abstract
Description
Technical Field
[0001] The present application relates to the field of antibody drugs. Specifically, the present application relates to a monoclonal antibody against human interleukin 36 receptor (IL-36R), a low-viscosity liquid preparation containing a high concentration of the monoclonal antibody, and applications thereof. Background Art
[0002] Interleukin-36 (IL-36) belongs to the IL-1 family (IL-1 family, IL1F), and is composed of IL-36 receptor agonists IL-36α (IL1F6), IL-36β (IL1F8), IL-36γ (IL1F9) and IL-36 receptor antagonist IL-36Ra (IL-36 receptor antagonist, IL1F5). Its structural pattern is similar to that of the classic IL-1 family: it lacks a signal peptide and cannot be secreted through the classic Golgi-endoplasmic reticulum pathway. It usually forms an inactive precursor first and then is activated by protease hydrolysis. IL-36 can be produced by a variety of cells, including monocytes, macrophages, T / B lymphocytes, keratinocytes, and epithelial cells. The receptor of IL-36 is composed of the specific receptor IL-36R (also known as IL-1RL2, Interleukin-1 receptor-like 2) and the IL-1 receptor auxiliary protein IL-1RAcP (IL-1 receptor accessory protein), both of which are composed of an extracellular region composed of three domains, a transmembrane region, and an intracellular Toll / IL-1 receptor (Toll / IL-1 receptor, TIR) domain. Proteolytically mature agonist IL-36 ligands (α, β, γ) bind to IL-36R to form a binary complex, which then recruits IL-1RAcP to assemble into a functional ternary complex. The intracellular TIR of IL-36R and IL-1RAcP interact with each other, aggregate the transduction adaptor protein myeloid differentiation factor 88 (MyD88) and interleukin-1 receptor associated kinase (IRAK), and then activate the downstream NF-κB (Nuclear factor kappa-B) and MAPK (Mitogen-activated protein kinase) signaling pathways. When IL-36 is expressed normally, it can perform host defense through inflammatory response. When IL-36 expression is dysregulated, it will stimulate its receptor-expressing cells (epithelial cells, fibroblasts, keratinocytes, monocytes, macrophages, dendritic cells, T cells) to produce inflammatory cytokines, chemokines, adhesion molecules, etc., thereby mediating pathological inflammatory responses and participating in the pathological process of chronic inflammatory and autoimmune diseases such as generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, and chronic obstructive pulmonary disease.
[0003] Spesolimab is a monoclonal antibody drug targeting IL-36R developed by Boehringer Ingelheim. It has been approved for marketing by the U.S. Food and Drug Administration (specification is 450 mg (7.5 ml) / bottle, and the administration method is intravenous injection), and has obtained priority review qualification from the China National Drug Administration. However, from the perspective of reducing the clinical use cost of biological preparations and improving patient compliance, the preferred dosage form of anti-human IL-36R monoclonal antibody drugs is a high-concentration protein water injection for subcutaneous injection. Since the dose for subcutaneous injection is usually in the range of 100 mg to 600 mg, and the maximum subcutaneous injection volume is generally limited to less than 2 ml, the concentration of anti-human IL-36R monoclonal antibody in the anti-human IL-36R monoclonal antibody injection administered by subcutaneous injection usually needs to reach 100 mg / mL or more, such as 100 to 150 mg / mL or 120 to 160 mg / mL.
[0004] A high concentration of monoclonal antibody usually causes an increase in the viscosity of the solution containing the monoclonal antibody, and too high a viscosity will make it impossible to manually push the syringe plunger to inject the drug subcutaneously. Therefore, for different anti-human IL-36R monoclonal antibodies, the formulation needs to be specially adjusted to obtain a low-viscosity liquid preparation containing a high concentration of the monoclonal antibody molecule, which can be used as an injection, especially a subcutaneous injection.
[0005] [1]Towne JE,Garka KE,Renshaw BR,et al.Interleukin(IL)-1F6,IL-1F8,and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathwayleading to NF-kappaB and MAPKs[J].Journal of Biological Chemistry,2004,279(14):13677-13688.
[0006] [2]Gabay C,Towne J E.Regulation and function of interleukin-36cytokines in homeostasis and pathological conditions[J].Journal ofLeukocyte Biology,2015,97(4):645.
[0007] [3]Henry CM, Sullivan GP, Clancy DM, et al. Neutrophil-DerivedProteases Escalate Inflammation through Activation of IL-36Family Cytokines[J]. Cell Reports, 2016, 14(4):708-722.
[0008] [4]Towne JE,Renshaw BR,Douangpanya J,et al.Interleukin-36(IL-36)Ligands Require Processing for Full Agonist(IL-36α,IL-36β,and IL-36γ)orAntagonist(IL-36Ra)Activity[J].Journal of Biological Chemistry,2011,286(49):42594-602.
[0009] [5]Buhl,AL,Wenzel,J.Interleukin-36in Infectious and InflammatorySkin Diseases[J].Frontiers in Immunology,2019.01162 Summary of the invention
[0010] The purpose of the present application is to provide a novel anti-human IL-36R monoclonal antibody, a pharmaceutical composition comprising the monoclonal antibody, and a low-viscosity liquid preparation containing a high concentration of the monoclonal antibody.
[0011] The technical solution of this application includes:
[0012] 1. An anti-human IL-36R monoclonal antibody comprising three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3), wherein:
[0013] The amino acid sequence of CDR-H1 (in this specification, CDR-H1 means heavy chain CDR1) is shown in SEQ ID NO: 1 (NYAMG);
[0014] The amino acid sequence of CDR-H2 (in this specification, CDR-H2 means heavy chain CDR2) is shown in SEQ ID NO: 2 (YISGGGSAYYASWAKG);
[0015] The amino acid sequence of CDR-H3 (in this specification, CDR-H3 means heavy chain CDR3) is shown in SEQ ID NO: 3 (WAIKSYFFGMDL);
[0016] The amino acid sequence of CDR-L1 (in this specification, CDR-L1 means light chain CDR1) is shown in SEQ ID NO: 4 (QASEYISSYLA);
[0017] The amino acid sequence of CDR-L2 (in this specification, CDR-L2 means light chain CDR2) is shown in SEQ ID NO: 5 (QASTLAS);
[0018] The amino acid sequence of CDR-L3 (in the present specification, CDR-L3 refers to light chain CDR3) is shown in SEQ ID NO: 6 (QTNNAIHTYGGA).
[0019] 2. The monoclonal antibody according to item 1, comprising a heavy chain variable region and a light chain variable region, wherein:
[0020] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 7, and its amino acid sequence is
[0021]
[0022] The amino acid sequence of the light chain variable region is shown in SEQ ID NO: 8, and its amino acid sequence is
[0023]
[0024]
[0025] 3. An isolated nucleic acid encoding any one of the aforementioned monoclonal antibodies.
[0026] 4. A host cell comprising the nucleic acid according to item 3.
[0027] The nucleic acid may be present on a vector. The vector may be of any type, for example, a recombinant vector such as an expression vector. Any of a variety of host cells may be used. In one embodiment, the host cell is a prokaryotic cell, for example, Escherichia coli (E. coli). In another embodiment, the host cell is a eukaryotic cell, for example, a mammalian cell, such as a Chinese hamster ovary (CHO) cell.
[0028] 5. A method for producing a monoclonal antibody, the method comprising culturing the host cell according to item 4 to thereby produce any one of the aforementioned monoclonal antibodies.
[0029] The method comprises expressing a recombinant vector encoding the anti-human IL-36R monoclonal antibody in a suitable host cell, thereby producing the monoclonal antibody. In certain embodiments, the method comprises culturing a host cell comprising a nucleic acid encoding the anti-human IL-36R monoclonal antibody, thereby expressing the nucleic acid. The method may further comprise recovering the anti-human IL-36R monoclonal antibody from the host cell culture or the host cell culture medium.
[0030] 6. A pharmaceutical composition comprising any one of the aforementioned monoclonal antibodies and a pharmaceutically acceptable carrier.
[0031] The pharmaceutical composition may further comprise an additional therapeutic agent (eg, a different anti-human IL-36R antibody).
[0032] 7. The pharmaceutical composition according to item 6, which is used for treating diseases related to IL-36R-mediated signal transduction.
[0033] 8. The pharmaceutical composition according to item 7, wherein the IL-36R-mediated signal transduction-related disease is selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease and chronic kidney disease,
[0034] Preferably, the IL-36R-mediated signal transduction-related disease is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, scleroderma, asthma or ankylosing spondylitis.
[0035] 9. Use of any of the aforementioned monoclonal antibodies in the preparation of a medicament for treating diseases associated with IL-36R-mediated signal transduction.
[0036] 10. The use according to item 9, wherein the IL-36R-mediated signal transduction-related disease is selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease and chronic kidney disease,
[0037] Preferably, the IL-36R-mediated signal transduction-related disease is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, scleroderma, asthma or ankylosing spondylitis.
[0038] 11. A method for treating a disease associated with IL-36R-mediated signal transduction, comprising:
[0039] The monoclonal antibody according to any of the preceding items or the pharmaceutical composition according to any of the preceding items is administered to a subject in need thereof.
[0040] 12. The method according to item 11, wherein the IL-36R-mediated signal transduction-related disease is selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease and chronic kidney disease,
[0041] Preferably, the IL-36R-mediated signal transduction-related disease is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, scleroderma, asthma or ankylosing spondylitis.
[0042] 13. A liquid preparation comprising an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody, a viscosity modifier and a buffer salt,
[0043] The concentration of the anti-human interleukin 36 receptor monoclonal antibody is 50 mg / mL or more. Further, the concentration of the anti-human IL-36R monoclonal antibody is 50-300 mg / mL (e.g., 50-200 mg / mL, or 100-150 mg / mL, or 110-160 mg / mL, or 120-170 mg / mL, or 130-180 mg / mL, or 140-190 mg / mL, or 150-200 mg / mL, or 160-210 mg / mL, or 170-180 mg / mL). 0-220 mg / mL, or 180-230 mg / mL, or 190-240 mg / mL), further, the anti-human IL-36R monoclonal antibody concentration is 120 mg / mL or more, further, the anti-human IL-36R monoclonal antibody concentration is 120-300 mg / mL, further, the anti-human IL-36R monoclonal antibody concentration is 120-200 mg / mL, further, the anti-human IL-36R monoclonal antibody concentration is 120-160 mg / mL,
[0044] The viscosity modifier has a concentration of 10-500 mM (e.g., 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330 mM, or 50-150 mM),
[0045] The anti-human interleukin-36 receptor monoclonal antibody comprises three heavy chain complementary determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementary determining regions CDR-L1, CDR-L2 and CDR-L3, and,
[0046] The amino acid sequence of the CDR-H1 is shown as NYAMG (SEQ ID NO: 1);
[0047] The amino acid sequence of the CDR-H2 is shown as YISGGGSAYYASWAKG (SEQ ID NO: 2);
[0048] The amino acid sequence of the CDR-H3 is shown as WAIKSYFFGMDL (SEQ ID NO: 3);
[0049] The amino acid sequence of the CDR-L1 is shown as QASEYISSYLA (SEQ ID NO: 4);
[0050] The amino acid sequence of the CDR-L2 is shown in QASTLAS (SEQ ID NO: 5);
[0051] The amino acid sequence of the CDR-L3 is shown as QTNNAIHTYGGA (SEQ ID NO: 6).
[0052] 14. The liquid preparation according to item 13, wherein the IL-36R monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein:
[0053] The amino acid sequence of the heavy chain variable region is shown as EVQLVESGGGLVQPGGSLRLSCAASGIDLSNYAMGWVRQAPGKGLEWVGYISGGGSAYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWAIKSYFFGMDLWGQGTLVTVSS (SEQ ID NO: 7);
[0054] The amino acid sequence of the light chain variable region is as follows: DIQMTQSPSSVSASVGDRVTITCQASEYISSYLAWYQQKPGKAPKLLIYQASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQTNNAIHTYGGAFGGGTKVEIK (SEQ ID NO: 8).
[0055] 15. The liquid preparation according to item 13 or 14, wherein the viscosity modifier is an amino acid protective agent.
[0056] 16. The liquid preparation according to item 15, wherein the amino acid protective agent is arginine hydrochloride, histidine, lysine, methionine, proline or a combination thereof, preferably arginine hydrochloride.
[0057] 17. The liquid preparation according to item 16, wherein the amino acid protective agent is arginine hydrochloride, and further, its concentration is 10 to 500 mM (e.g., 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 150, 160, 170, 180, 190, 200 mM).
[0058] 18. The liquid preparation according to item 13 or 14, wherein the viscosity modifier is sodium chloride, and further, its concentration is 50-200 mM (e.g., 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 mM).
[0059] 19. The liquid preparation according to item 13 or 14, wherein the viscosity modifier is sucrose, and further, the concentration thereof is 10 to 100 mg / mL (e.g., 20 mg / mL, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL).
[0060] 20. The liquid preparation according to item 13 or 14, wherein the viscosity modifier is sorbitol, and further, the concentration thereof is 40-50 mg / mL (e.g., 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 mg / mL).
[0061] 21. The liquid preparation according to any one of items 13 to 20, wherein the buffer salt is sodium acetate, acetic acid, or a combination thereof.
[0062] 22. The liquid preparation according to item 21, wherein the buffer salt concentration is 15 to 15 mM (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 mM), preferably 20 mM.
[0063] 23. The liquid preparation according to any one of items 13 to 22, wherein the liquid preparation preferably does not contain foreign proteins, and further, the concentration of foreign proteins in the liquid preparation is <100 ppm.
[0064] 24. The liquid preparation according to any one of items 13 to 23, which has a pH of 5.0 to 6.5 (eg, 5.0, 5.2, 5.5, 5.8 or 6.0).
[0065] 25. The liquid preparation according to any one of items 13 to 24, which has a viscosity of 10 cP or less.
[0066] 26. According to the liquid preparation described in item 13 or 14, a viscosity regulator mother solution with a final concentration of 50 to 300 mmol / L is added during ultrafiltration to reduce the viscosity value of the anti-human interleukin 36 receptor monoclonal antibody protein when the concentration range is 120 mg / ml to 200 mg / ml, and to improve the stability of the protein molecule.
[0067] 27. The liquid preparation according to item 26, wherein the viscosity modifier is an amino acid protective agent, further comprising arginine hydrochloride, histidine, lysine, methionine, proline or a combination thereof.
[0068] 28. The liquid preparation according to item 27, wherein the amino acid protective agent is a combination of 100-200 mM (e.g., 150 mM) arginine hydrochloride, 2-50 mM methionine (e.g., 10 mM) and 10-50 mM (e.g., 20 mM) histidine
[0069] 29. A method for reducing the viscosity value of the liquid preparation according to item 13 or 14, wherein a viscosity regulator is added during the ultrafiltration liquid exchange process, wherein the viscosity regulator is preferably arginine or arginine hydrochloride, and the drug solution buffer system before high-concentration concentration is 20 mM histidine-hydrochloric acid buffer, citric acid buffer, phosphate buffer or sodium acetate-acetate buffer.
[0070] 30. A method for reducing the viscosity of a liquid preparation according to item 13 or 14, wherein a viscosity regulator is added during an ultrafiltration liquid exchange process, wherein the pH of the liquid buffer is 5.0-6.5.
[0071] 31. The liquid preparation according to item 13 or 14, comprising 180 mg / mL or more of the anti-IL-36 monoclonal antibody and having a viscosity of 15 cP or less.
[0072] 32. The liquid preparation according to item 13 or 14, comprising 150 mg / mL or more of the anti-IL-36 monoclonal antibody and having a viscosity of 10 cP or less.
[0073] 33. A liquid preparation comprising: 120 mg / mL or more (preferably 300 mg / mL or less, more preferably 200 mg / mL or less, more preferably 160 mg / mL or less) of the anti-human IL-36 monoclonal antibody according to item 1 or 2, and 10 to 500 mM of an amino acid protective agent and a surfactant.
[0074] 34. Use of the liquid preparation described in any one of items 13 to 33 in the preparation of a medicament for treating IL-36R-mediated signal transduction-related diseases.
[0075] 35. The use according to item 34, wherein the IL-36R-mediated signal transduction-related disease is selected from dermatitis, psoriasis, inflammatory bowel disease, arthritis, systemic lupus erythematosus, inflammatory lung disease and chronic kidney disease.
[0076] 36. The use according to item 34, wherein the IL-36R-mediated signal transduction-related disease is selected from generalized pustular psoriasis, palmoplantar pustulosis, atopic dermatitis, inflammatory bowel disease, chronic obstructive pulmonary disease, psoriasis vulgaris, psoriatic arthritis, multiple sclerosis, rheumatoid arthritis, scleroderma, asthma and ankylosing spondylitis.
[0077] The present application provides a new anti-human IL-36R monoclonal antibody, which has a comparable affinity for binding to IL-36R as the anti-human IL-36R monoclonal antibody Spesolimab in the prior art, and has a better neutralization activity at the cellular level than Spesolimab. It should be noted that Spesolimab is a monoclonal antibody drug targeting IL-36R developed by Boehringer Ingelheim. The Phase III clinical trial NAVIGATOR of Spesolimab for the treatment of generalized pustular psoriasis in adults was successful. It has been approved for marketing by the U.S. Food and Drug Administration and has obtained priority review status from the China National Drug Administration.
[0078] The monoclonal antibody of the present application (e.g., QX009N (HZD25-54)) can be a humanized monoclonal antibody of the IgG1 (immunoglobulin G1) type targeting IL-36R (interleukin-36 receptor), has a high affinity for IL-36R, can specifically bind to IL-36R, and block the IL-36 inflammatory pathway signal. HZD25-54 binds to IL-36R, competitively blocks the binding of receptor agonists (IL-36α, β, γ) to IL-36R, downregulates downstream pro-inflammatory signaling pathways and pro-fibrotic signaling pathways, inhibits inflammatory responses mediated by epithelial cells / fibroblasts / immune cells, thereby reducing the release of pathogenic cellular inflammatory factors in inflammatory diseases / skin diseases, and achieving the purpose of controlling the disease.
[0079] The monoclonal antibody of the present application shows a neutralizing activity superior to that of Spesolimab (prepared by expressing the sequence disclosed in patent US9023995B2) at the cellular level, and is expected to show good clinical effects in preventing and treating related diseases.
[0080] The anti-human IL-36R monoclonal antibody liquid preparation provided in the present application comprises a high concentration (120 mg / mL or more, preferably 150 mg / mL or more) of anti-human interleukin 36 receptor monoclonal antibody, and by adding a suitable viscosity regulator (preferably arginine hydrochloride, sodium chloride, sucrose, sorbitol or a combination thereof), the antibody viscosity value under the same protein concentration condition is reduced to less than 60% of the original, so that it has a low viscosity (less than 10 cP), can be applied to ultrafiltration membrane concentration processes that cannot be used under high viscosity, can be easily injected with a syringe, and can therefore be used as an injection, especially a subcutaneous injection. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] The accompanying drawings are used to better understand the present application and do not constitute an improper limitation on the present application.
[0082] Figure 1 It is a diagram showing the results of nucleic acid electrophoresis for constructing the HZD25-54 transient expression plasmid. Among them, M: Marker; Band 1: PCR product 25VH-Hu12; Band 2: pQX2.1, HindIII / BamHI; Band 3: PCR product 25VK-Hu17; Band 4: pQX2.3, HindIII / BsiWI.
[0083] Figure 2 It is a flowchart of transient expression.
[0084] Figure 3 This is the electrophoresis detection diagram of QX009N (HZD25-54).
[0085] Figure 4 The graph shows the results of QX009N (HZD25-54) and Spesolimab analogs neutralizing human IL-36 (α, β, γ)-induced STAT3 phosphorylation activity in HT29 reporter cells.
[0086] Figure 5 The graph shows the results of QX009N (HZD25-54) and Spesolimab analogs neutralizing the activity of CXCL-1 and IL-8 released by HT29 cells induced by human IL-36 (α, β, γ).
[0087] Figure 6It is a graph showing that QX009N (HZD25-54) and Spesolimab analogs neutralize the activity of A431 cells releasing CXCL-1 and IL-8 induced by human IL-36 (α, β, γ).
[0088] Figure 7 It is a graph showing that QX009N (HZD25-54) and Spesolimab analogs neutralize the activity of human IL-36β inducing IL-8 release from PBMC cells. DETAILED DESCRIPTION
[0089] The following is a description of the exemplary embodiments of the present application, including various details of the embodiments of the present application to facilitate understanding, which should be considered as merely exemplary. Therefore, it should be recognized by those of ordinary skill in the art that various changes and modifications can be made to the embodiments described herein without departing from the scope and spirit of the present application. Similarly, for clarity and conciseness, the description of well-known functions and structures is omitted in the following description.
[0090] The technical terms mentioned in this specification have the same meanings as those generally understood by those skilled in the art. In case of any conflict, the definitions in this specification shall prevail.
[0091] Specifically, the present application also provides a liquid preparation comprising an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody, wherein the liquid preparation comprises an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody having a protein concentration of 50-300 mg / ml, a viscosity modifier having a concentration of 10-500 mM, and a buffer salt having a concentration of 20 mM;
[0092] Further, in the liquid preparation, the protein concentration of the anti-human interleukin 36 receptor (IL-36R) monoclonal antibody can be 100 mg / ml, 110 mg / ml, 120 mg / ml, 130 mg / ml, 140 mg / ml, 150 mg / ml, 160 mg / ml, 170 mg / ml, 180 mg / ml, 190 mg / ml, 200 mg / ml, etc.;
[0093] Furthermore, in the liquid preparation, the concentration of the viscosity modifier can be 5mM, 10mM, 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 150mM, 200mM, 250mM, 300mM, etc.
[0094] Furthermore, in the liquid preparation, the 20 mM buffer salt may be sodium acetate, acetic acid or a combination thereof.
[0095] Furthermore, the pH of the liquid preparation may be 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4 or 6.5.
[0096] In the above-mentioned liquid preparation provided in the present application, the anti-human interleukin-36 receptor monoclonal antibody comprises three heavy chain complementary determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementary determining regions CDR-L1, CDR-L2 and CDR-L3, wherein:
[0097] a. The amino acid sequence of CDR-H1 is shown in SEQ ID NO: 1 (NYAMG);
[0098] b. The amino acid sequence of CDR-H2 is shown in SEQ ID NO: 2 (YISGGGSAYYASWAKG);
[0099] c. The amino acid sequence of CDR-H3 is shown in SEQ ID NO: 3 (WAIKSYFFGMDL);
[0100] d. The amino acid sequence of CDR-L1 is shown in SEQ ID NO: 4 (QASEYISSYLA);
[0101] e. The amino acid sequence of CDR-L2 is shown in SEQ ID NO: 5 (QASTLAS);
[0102] f. The amino acid sequence of CDR-L3 is shown in SEQ ID NO: 6 (QTNNAIHTYGGA).
[0103] In the application, human interleukin-36 receptor (hIL-36R, sometimes abbreviated as IL-36R) refers to a membrane receptor derived from humans, whose extracellular domain amino acid sequence is shown in SEQ ID NO: 9, wherein the underlined portion represents a signal peptide.
[0104] SEQ ID NO:9:
[0105]
[0106] In the present specification, “anti-human IL-36R monoclonal antibody” means a monoclonal antibody that can bind to human IL-36R with sufficient affinity so that the monoclonal antibody can be used as a diagnostic agent and / or therapeutic agent targeting human IL-36R.
[0107] The anti-human IL-36R monoclonal antibody of the present application does not bind to proteins that are unrelated to the target. Here, "unrelated proteins" refer to proteins other than human IL-36R as the target; here, "no binding" means: when the binding ability of the anti-human IL-36R monoclonal antibody of the present application to human IL-36R as its target is taken as 100%, the binding ability of the anti-human IL-36R monoclonal antibody of the present application to the unrelated protein is less than 10%, for example, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0.
[0108] The anti-human IL-36R monoclonal antibody of the present application may not bind to IL-36R of other animal species. Here, "other animal species" refers to animal species other than humans, such as marmosets, cynomolgus monkeys, pigs, dogs, rabbits, rats, mice, guinea pigs, etc.; here, "no binding" means: when the binding ability of the anti-human IL-36R monoclonal antibody of the present application to human IL-36R as its target is taken as 100%, the binding ability of the anti-human IL-36R monoclonal antibody of the present application to IL-36R of other animal species is less than 10%, such as 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0.
[0109] The human IL-36R monoclonal antibody of the present application may have, for example, an equilibrium dissociation constant (K) of ≤1 μM, ≤100 nM, ≤50 nM, or ≤40 nM. D ).
[0110] The experimental results show that the anti-human IL-36R monoclonal antibody of the present application can specifically bind to human IL-36R.
[0111] The anti-human IL-36R monoclonal antibody of the present application is comparable to or superior to similar monoclonal antibody products on the market in many biological activities, such as neutralizing the activity of STAT3 phosphorylation induced by human IL-36 (α, β, γ) in cells, neutralizing the activity of CXCL-1 and IL-8 induced by human IL-36 (α, β, γ) in cells, and neutralizing the activity of IL-8 induced by human IL-36β in human PBMC cells.
[0112] In a specific embodiment, the amino acid sequence of the heavy chain of the anti-human IL-36R monoclonal antibody of the present application may be as shown in SEQ ID NO: 10; and the amino acid sequence of the light chain may be as shown in SEQ ID NO: 11.
[0113] SEQ ID NO: 10
[0114]
[0115] SEQ ID NO: 11
[0116]
[0117]
[0118] Among them, SEQ ID NO: 10 and 11 are both humanized sequences. In order to eliminate the ADCC and CDC effects of the antibody, back mutations were performed on specific sites in the framework region and site-directed mutations were performed in the CDR region.
[0119] In this specification, an "isolated" antibody is one that has been separated from the components of its natural environment. In certain embodiments, the antibody is purified to greater than 95% or 99% purity, as determined by, for example, electrophoresis (e.g., SDS-PAGE isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed phase HPLC). For a review of methods for evaluating antibody purity, see, for example, Flatman et al., J. Chromatogr. B 848: 79-87 (2007).
[0120] In this specification, "monoclonal antibody" means an antibody derived from a population of substantially homologous antibodies, that is, each antibody constituting the population is identical and / or binds to the same epitope, except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of monoclonal antibody products), such variants are usually present in trace amounts. Different from polyclonal antibody products that generally include different antibodies for different determinants (epitopes), each monoclonal antibody of a monoclonal antibody product is directed to a single determinant on an antigen. Thus, the modifier "monoclonal" indicates that the antibody is derived from a substantially homologous antibody population, and should not be interpreted as requiring the antibody to be produced by any ad hoc method. For example, the monoclonal antibody to be used according to the present application can be prepared by a variety of techniques, including, but not limited to, hybridoma methods, recombinant DNA methods, phage display methods, and methods using transgenic animals comprising all or part of human immunoglobulin loci, and such methods and other exemplary methods for preparing monoclonal antibodies are described herein.
[0121] In this specification, "affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, "binding affinity" as used in this specification refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be expressed by the equilibrium dissociation constant (K D Affinity can be measured by common methods known in the art.
[0122] In this specification, "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from the components of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location different from its natural chromosomal location.
[0123] As used herein, "isolated nucleic acid encoding an anti-IL-36R monoclonal antibody" refers to one or more nucleic acid molecules encoding the heavy and light chains of the antibody, including such nucleic acid molecules in a single vector or separate vectors, and such nucleic acid molecules present in one or more locations in a host cell.
[0124] In this specification, "vector" means a nucleic acid molecule capable of amplifying another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that integrate into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."
[0125] In this specification, "host cell", "host cell line" and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including the offspring of such cells. Host cells include "transformants" and "transformed cells", which include the primary transformed cells and the offspring derived therefrom (regardless of the number of generations). Offspring may not be identical to the parental cell in terms of nucleic acid content, but may contain mutations. Offspring of mutants screened or selected for the initially transformed cells with the same function or biological activity are included in this specification.
[0126] In the present specification, "pharmaceutical composition" means a preparation which is in a form that enables the biological activity of the active ingredient contained therein to exert its effect and which does not contain additional components that are unacceptably toxic to the subject to which the preparation is to be administered.
[0127] In this specification, "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical composition other than an active ingredient, which is non-toxic to a subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.
[0128] In this application, "monoclonal antibody" is generally a human antibody, which can be prepared using techniques known to those skilled in the art. For example, human antibodies are generally described in van Dijk, MA and van de Winkel, JG, Curr. Opin. Pharmacol. 5:368-374 (2001) and Lonberg, N., Curr. Opin. Immunol. 20:450-459 (2008).
[0129] Antibodies can be prepared by administering immunogens to transgenic animals that have been modified to stimulate the production of complete human antibodies or complete antibodies with human variable regions in response to antigenic attack. These animals typically contain a portion or all of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or are present outside the chromosomes or randomly integrated in the animal. In such transgenic mice, the endogenous immunoglobulin loci are generally inactivated. For a review of methods for obtaining human antibodies from transgenic animals, see Lonberg, N., Nat. Biotech. (Nature Biotechnology) 23: 1117-1125 (2005). See also, for example, the XENOMOUSE described in U.S. Patent Nos. 6,075,181 and 6,150,584. TM Technology; US Patent No. 5,770,429 describes Technology; US Patent No. 7,041,870 describes Technology, and U.S. Patent Application Publication No. US2007 / 0061900 described The human variable regions from intact antibodies generated by such animals can be further modified, for example, by combining with a different human constant region.
[0130] Human antibodies can also be prepared by hybridoma-based methods. Human myeloma and mouse-human hybrid myeloma cells for producing human monoclonal antibodies have been described (see, e.g., Kozbor, D., J. Immunol. 133: 3001-3005 (1984); Brodeur, BR et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York (1987), pp. 51-63; Boerner, P. et al., J. Immunol. 147: 86-95 (1991)). Human antibodies produced via human B cell hybridoma technology are also described in Li, J. et al., Proc. Natl. Acad. Sci. USA 103: 3557-3562 (2006). Other methods include those described in, for example, U.S. Pat. No. 7,189,826 (which describes the production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26 (4); 265-268 (which describes human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers, HP and Brandlein, S., Histology and Histopathology 20: 927-937 (2005); Vollmers, HP and Brandlein, S., Methods and Findings in Experimental and Clinical Pharmacology 27: 185-191 (2005).
[0131] Human antibodies can also be made by isolating Fv clone variable domain sequences selected from human-derived phage display libraries, and such variable domain sequences can then be combined with the desired human constant domains.
[0132] Human antibodies can also be selected based on self-antibody libraries, that is, human antibodies can be isolated by screening combinatorial libraries for antibodies with desired one or more activities. For example, various methods for producing phage display libraries and screening such libraries for antibodies with desired binding characteristics are known in the art. This method is reviewed in, for example, Hoogenboom, HR, et al., Methods in Molecular Biology 178: 1-37 (2001), and is further described in, for example, McCafferty, J., et al., Nature 348: 552-554 (1990); Clackson, T., et al., Nature 352: 624-628 (1991); Marks, JD, et al., J. Mol. Biol. 222: 581-597 (1992); Marks, JD and Bradbury, A., Methods in Molecular Biology 248:161-175(2003); Sidhu, SS et al., J. Mol. Biol. 338: 299-310 (2004); Lee, CV et al., J. Mol. Biol. 340: 1073-1093 (2004); Fellouse, FA, Proc. Natl. Acad. Sci. USA 101:12467-12472 (2004); and Lee, CV et al., J. Immunol. Methods 284:119-132 (2004).
[0133] In certain phage display methods, the repertoires of VH and VL genes are cloned separately by polymerase chain reaction (PCR) and randomly recombined in a phage library, which is then screened for antigen-binding phage, as described in Winter, G. et al., Ann. Rev. Immunol. 12: 433-455 (1994). Phages typically display antibody fragments as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the need to construct hybridomas. Alternatively, non-immunized repertoires can be cloned (e.g., from humans) to provide a single source of antibodies to a large number of non-self and also self-antigens without any immunization, as described by Griffiths, AD et al., EMBO J, 12: 725-734 (1993). Finally, unimmunized libraries can also be generated synthetically by cloning unrearranged V gene segments from stem cells and using PCR primers containing random sequences to encode highly variable CDR3 regions and achieve rearrangement in vitro, as described by Hoogenboom, HR and Winter, G., J. Mol. Biol. 227:381-388 (1992). Patent publications describing human antibody phage libraries include, for example, U.S. Patent No. 5,750,373 and U.S. Patent Publication Nos. 2005 / 0079574, 2005 / 0119455, 2005 / 0266000, 2007 / 0117126, 2007 / 0160598, 2007 / 0237764, 2007 / 0292936 and 2009 / 0002360.
[0134] The antibody can also be a multispecific antibody, such as a bispecific antibody. Bispecific antibodies are monoclonal antibodies with binding specificity to at least two different sites. The techniques for generating multispecific antibodies include, but are not limited to, the recombinant co-expression of two pairs of immunoglobulin heavy chains-light chains with different specificities (see Milstein, C. and Cuello, AC, Nature 305: 537-540 (1983); WO 93 / 08829; and Traunecker, A. et al., EMBO J. 10: 3655-3659 (1991)) and "node-into-hole" engineering (see, e.g., U.S. Pat. No. 5,731,168). It can also be achieved by engineering electrostatic manipulation effects for generating antibody Fc-heterodimer molecules (WO 2009 / 089004); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980 and Brennan, M. et al., Science 229: 81-83 (1985)); using leucine zippers to generate bispecific antibodies (see, e.g., Kostelny, SA et al., J. Immunol. 148: 1547-1553 (1992)); using "diabody" technology for generating bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993)); and using single-chain Fv (scFv) dimers (see, e.g., Gruber, M. et al., J. Immunol. 152:5368-5374 (1994)); and preparing trispecific antibodies (as described, e.g., in Tutt, A. et al., J. Immunol. 147:60-69 (1991)) to generate multispecific antibodies.
[0135] The monoclonal antibodies described in this application also include engineered antibodies having three or more functional antigen binding sites, including "octopus antibodies" (see, e.g., US 2006 / 0025576).
[0136] The antibodies in the present application may also include the multispecific antibodies described in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, WO 2010 / 112193, WO 2010 / 115589, WO 2010 / 136172, WO 2010 / 145792, and WO 2010 / 145793, WO 2011 / 117330, WO 2012 / 025525, WO 2012 / 025530, WO 2013 / 026835, WO 2013 / 026831, WO 2013 / 164325, or WO 2013 / 174873.
[0137] The monoclonal antibodies described in the present application may also be antibody variants, for example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. The amino acid sequence variants of the antibody can be prepared by introducing suitable modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletion, and / or insertion and / or substitution of residues in the amino acid sequence of the antibody. Any combination of deletion, insertion, and substitution can be performed to obtain the final construct, as long as the final construct has the desired characteristics, such as antigen binding. Therefore, in certain embodiments, there are provided antibody variants with one or more amino acid substitutions, and the sites of interest for substitution mutations include HVR and FR, for example, amino acid substitutions can be introduced into the antibody of interest and screened for products with desired activity, for example, retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.
[0138] In the present application, the "viscosity modifier" is a component that can effectively reduce the viscosity of the anti-human interleukin 36 receptor (IL-36R) monoclonal antibody liquid preparation. In some specific embodiments, the viscosity modifier is an amino acid protective agent (such as arginine hydrochloride, histidine, lysine, methionine, proline or a combination thereof) or other additives that have a viscosity regulating effect on the liquid preparation (such as sodium chloride, sucrose, sorbitol, etc.).
[0139] In the present application, "contaminants" refer to proteins other than the target protein that remain during the purification process of the target protein, such as exogenous host proteins.
[0140] Example
[0141] The present application provides a general and / or specific description of the materials and test methods used in the experiments. In the following examples, unless otherwise specified, % means wt%, i.e., weight percentage; the experimental methods used are conventional methods unless otherwise specified. The materials, reagents, etc. used are conventional reagent products that can be purchased commercially unless otherwise specified.
[0142] Example 1 Preparation of anti-human IL-36R monoclonal antibody QX009N
[0143] Quanxin Biotech used the self-expressed human interleukin 36 receptor (hIL-36R-Rabbit Fc) as an immunogen to immunize New Zealand rabbits, and used B cell cloning technology to obtain antigen-binding specific antibody clones, and then screened out monoclonal antibodies that bind to human IL-36R and have human IL-36R inhibitory activity. The cell supernatant was analyzed and screened by Binding ELISA and HT29 cell release of IL-8 to select the target clone. The above immunization and screening processes were entrusted to commercial companies.
[0144] Ten clones were selected for recombinant expression and sequencing. It was determined that clone 25 had the best cell neutralization activity. Therefore, clone 25 was humanized. NCBI IgBlast was used to perform homology alignment of human IgG germline sequences, and IGHV3-66*01 was selected as a heavy chain CDR transplantation template, and the CDR region of the 25# clone heavy chain (i.e., CDR-H1 (SEQ ID No: 1), CDR-H2 (SEQ ID No: 2), and CDR-H3 (SEQ ID No: 3)) was transplanted into the framework region of IGHV3-66*01; IGKV1-12*01 was selected as a light chain CDR transplantation template, and the CDR region of the 25# clone light chain (i.e., CDR-L1 (SEQ ID No: 4), CDR-L2 (SEQ ID No: 5), and CDR-L3 (SEQ ID No: 6)) was transplanted into the framework region of IGKV1-12*01; back mutations were performed on specific sites in the framework region and site-directed mutations were performed in the CDR region to obtain the variable region of the monoclonal antibody QX009N of the present application. Finally, the sequence of the humanized heavy chain variable region is shown in SEQ ID NO: 7; the amino acid sequence of the humanized light chain variable region is shown in SEQ ID NO: 8.
[0145] The heavy chain gene (SEQ ID NO: 10) and the light chain variable region gene (SEQ ID NO: 8) were obtained by PCR amplification. The heavy chain expression plasmid pQX2.1 was double-digested with HindIII and BamHI; the light chain expression plasmid pQX2.3 was double-digested with HindIII and BsiWI; the PCR amplified genes were respectively inserted into the corresponding expression plasmids using Infusion recombinase to construct the heavy chain expression plasmid pQX2.1-25VH-Hu12 and the light chain expression plasmid pQX2.3-25VK-Hu17.
[0146] The results of nucleic acid electrophoresis detection of PCR amplified heavy chain gene fragments, light chain variable region gene fragments and double enzyme digested plasmids are as follows Figure 1 As shown. Figure 1 From the results, we can see the PCR amplification results of the antibody heavy chain and light chain variable regions and the results of double enzyme digestion of the heavy chain and light chain expression plasmids. Among them, the plasmid size of the heavy chain and light chain is about 5000bp, the heavy chain is about 1469bp, and the light chain variable region is about 441bp.
[0147] The heavy chain expression plasmid pQX2.1-25VH-Hu12 (the amino acid sequence of the expressed heavy chain is shown in SEQ ID NO: 10) and the light chain expression plasmid pQX2.3-25VK-Hu17 (the amino acid sequence of the expressed light chain is shown in SEQ ID NO: 11) with the correct sequence were co-transfected into ExpiCHO-S cells. One day before transfection, ExpiCHO-S cells were diluted to 3×10 6 On the day of transfection, the cell density was diluted to 6×10 6 cells / ml, 25ml cells were placed in a 125ml shake flask and waited for transfection. The transfection and expression process is as follows Figure 2 shown.
[0148] On the 6th day after transfection, the culture supernatant was harvested and purified by Protein A. The purified antibody was detected by SDS-PAGE electrophoresis and named QX009N (HZD25-54). The results of protein electrophoresis for detecting the antibody were as follows: Figure 3 As shown. Protein electrophoresis was detected using denaturing reducing gel. Figure 3 The results showed two bands with sizes of approximately 50 kDa and 25 kDa, respectively, which were consistent with the theoretical molecular weights of the heavy chain (49.0 kDa) and the light chain (23.4 kDa).
[0149] Example 2 Equilibrium dissociation constant (K D )
[0150] Biacore T200 was used to detect the affinity of QX009N (HZD25-54) to human IL-36R, and all processes were carried out at 25°C. A commercial Protein A chip was used to fix an appropriate amount of antibody by capture method, so that Rmax was around 50RU, and the capture flow rate was 10μl / min. The antigen was gradient diluted, and the instrument flow rate was switched to 30μl / min. It flowed through the reference channel and the channel of the fixed antibody in order from low to high concentration, and the buffer solution was used as a negative control. After each binding and dissociation was completed, the chip was regenerated with pH1.5 glycine. Use the instrument's own analysis software to select the 1:1 binding model in the Kinetics option for fitting, and calculate the antibody binding rate constant k a , the dissociation rate constant k d and the dissociation equilibrium constant K D value.
[0151] In addition, the affinity of QX009N (HZD25-54) was compared with that of Spesolimab, a monoclonal antibody against human IL-36R that is currently in Phase III clinical trials. The detection method for known antibodies was the same as that for QX009N, and the results are shown in Table 1. Spesolimab was constructed based on the B6 sequence provided by patent US9023995B2, and was obtained by transiently transfecting ExpiCHO-S cells.
[0152] Table 1 Affinity of anti-human IL-36R monoclonal antibodies binding to human IL-36R
[0153] Sample name <![CDATA[k a (10 5 M -1 S -1 )]]> <![CDATA[k d (10 -5 S -1 )]]> <![CDATA[K D (10 -10 M)]]> QX009N 1.14 3.58 3.13 Spesolimab 0.36 3.11 8.62
[0154] The data in the table are: each sample was tested three times and the average value was calculated.
[0155] Example 3 QX009N (HZD25-54) and Spesolimab analogs neutralize human IL-36 (α, β, γ)-induced STAT3 phosphorylation activity in HT29 reporter cells
[0156] The HT29 reporter gene cell line was used to determine the activity of QX009N (HZD25-54) in antagonizing the intracellular signaling molecule STAT3 phosphorylation mediated by human IL-36 (α, β, γ) through IL-36R-IL-1RAcp: 40,000 cells were added to a 96-well cell culture plate at a volume of 100 μl per well, and then cultured overnight at 37°C and 5% CO2. Antibodies were added to the cells for incubation for 1 hour, where the final concentration of the antibodies ranged from 0 to 10,000 ng / ml. After the incubation, 50 μl / well of recombinant human IL-36 mixture (containing 2 ng / ml recombinant human IL-36α, 1 ng / ml recombinant human IL-36β, and 40 ng / ml recombinant human IL-36γ) was added, and then cultured for 24 hours at 37°C and 5% CO2. Discard the cell culture supernatant, add 120 μl ONE-Glo-Luciferase Reagent to each well, act for 10 min, take 80 μl from each well to a white 96-well plate, detect the luminescence fluorescence signal value and draw a dose-effect curve to analyze the antagonistic activity of the antibody. The dose-effect curve is shown in Figure 4 shown.
[0157] Figure 4 The results shown in the figure show that QX009N (HZD25-54) can inhibit the phosphorylation of STAT3 induced by human IL-36 (α, β, γ) in HT29 reporter gene cells. The IC value of QX009N (HZD25-54) in inhibiting the phosphorylation of STAT3 induced by human IL-36 (α, β, γ) in HT29 reporter gene cells is 50 The IC of 2.16ng / ml Spesolimab analogs inhibiting STAT3 phosphorylation induced by human IL-36 (α, β, γ) in HT29 reporter cells 50 It is 15.67ng / ml.
[0158] Example 4 QX009N (HZD25-54) and Spesolimab analogs neutralize the activity of CXCL-1 and IL-8 release induced by human IL-36 (α, β, γ) in HT29 cells
[0159] The HT29 cell line was used to determine whether QX009N (HZD25-54) antagonized human IL-36 (α, β, γ) and induced HT29 cells to release CXCL-1 and IL-8 through IL-36R-IL-1RAcp: 40,000 cells were added to a 96-well cell culture plate at a volume of 100 μl per well, and then cultured overnight at 37°C and 5% CO2. Antibodies were added to the cells for incubation for 1 hour, where the final concentration of the antibodies ranged from 0 to 10,000 ng / ml. After the incubation, 50 μl / well of a recombinant human IL-36 mixture (containing 1 ng / ml recombinant human IL-36α, 0.2 ng / ml recombinant human IL-36β, and 4 ng / ml recombinant human IL-36γ) was added, and then cultured for 24 hours at 37°C and 5% CO2. The cell culture supernatant was collected, and the expression of CXCL-1 and IL-8 in the supernatant was detected by sandwich ELISA method, and the dose-effect curve was drawn to analyze the antagonistic activity of the antibody. The dose-effect curve is shown in Figure 5 shown.
[0160] Figure 5 The results shown in the figure show that QX009N (HZD25-54) can inhibit the release of CXCL-1 and IL-8 induced by human IL-36 (α, β, γ) in HT29 cells. The IC values of QX009N (HZD25-54) for inhibiting the release of CXCL-1 and IL-8 induced by human IL-36 (α, β, γ) in HT29 cells are 50 The IC values of Spesolimab analogs for inhibiting the release of CXCL-1 and IL-8 by HT29 cells induced by human IL-36 (α, β, γ) were 2.21 ng / ml and 1.53 ng / ml, respectively. 50 They are 12.29ng / ml and 11.47ng / ml respectively.
[0161] Example 5 QX009N (HZD25-54) and Spesolimab analogs neutralize the activity of A431 cells releasing CXCL-1 and IL-8 induced by human IL-36 (α, β, γ)
[0162] A431 cell line was used to measure QX009N (HZD25-54) antagonizing human IL-36 (α, β, γ) to induce A431 cells to release CXCL-1 and IL-8 through IL-36R-IL-1RAcp: 40,000 cells were added to a 96-well cell culture plate at a volume of 100 μl per well, and then cultured overnight at 37°C and 5% CO2. Antibodies were added to the cells for incubation for 1 hour, where the final concentration of the antibodies ranged from 0 to 10,000 ng / ml. After the incubation, 50 μl / well of recombinant human IL-36 mixture (containing 20 ng / ml recombinant human IL-36α, 2 ng / ml recombinant human IL-36β, and 50 ng / ml recombinant human IL-36γ) was added, and then cultured for 24 hours at 37°C and 5% CO2. The cell culture supernatant was collected, and the expression of CXCL-1 and IL-8 in the supernatant was detected by sandwich ELISA method, and the dose-effect curve was drawn to analyze the antagonistic activity of the antibody. The dose-effect curve is shown in Figure 6 shown.
[0163] Figure 6 The results shown in the figure show that QX009N (HZD25-54) can inhibit the release of CXCL-1 and IL-8 from A431 cells induced by human IL-36 (α, β, γ), and the IC values of QX009N (HZD25-54) are as follows: 50 The IC values of Spesolimab analogs for inhibiting the release of CXCL-1 and IL-8 by A431 cells induced by human IL-36 (α, β, γ) were 4.12 ng / ml and 2.89 ng / ml, respectively. 50 They are 22.46ng / ml and 16.02ng / ml respectively.
[0164] Example 6 QX009N (HZD25-54) and Spesolimab analogs neutralize the activity of human IL-36β in inducing IL-8 release from human PBMC cells
[0165] Human PBMC cells were used to determine the activity of QX009N (HZD25-54) in antagonizing human IL-36β to induce IL-8 release from human PBMC cells through IL-36R-IL-1RAcp: PBMCs were separated from human venous blood (from healthy adult volunteers) by density gradient centrifugation, and 100 μl and 200,000 cells of PBMCs were added to a 96-well cell culture plate at each well. Antibodies were added to the PBMCs and incubated for 1 hour, wherein the final concentration of the antibodies ranged from 0 to 5000 ng / ml. After the incubation, 50 μl / well of 10 ng / ml recombinant human IL-36β was added, and then cultured at 37°C and 5% CO2 for 24 hours. The cell culture supernatant was collected, and the expression of IL-8 in the supernatant was detected by sandwich ELISA and a dose-effect curve was drawn to analyze the antagonistic activity of the antibody. The dose-effect curve is shown in FIG. Figure 7 shown.
[0166] from Figure 7 The results shown in the figure show that QX009N (HZD25-54) can inhibit the release of IL-8 from human PBMC cells induced by human IL-36β. The IC value of QX009N (HZD25-54) in inhibiting the release of IL-8 from human PBMC cells induced by human IL-36β is 50 The IC value of Spesolimab analogs for inhibiting the release of IL-8 from human PBMC induced by human IL-36β was 4.69 ng / ml. 50 It is 26.59ng / ml.
[0167] Example 7 Preparation of a low viscosity liquid formulation containing high concentration of QX009N (HZD25-54)
[0168] CHO cells were used as host cells and fermented in a 2L bioreactor to produce the antibody QX009N obtained in Example 1. The clarified fermentation broth was obtained by centrifuge or deep membrane filtration. The target protein was captured by Protein A chromatography, and then the virus was inactivated by low pH. Finally, impurities were removed by anion and cation chromatography to obtain an intermediate sample to be ultrafiltered.
[0169] Ultrafiltration concentration: The intermediate sample is ultrafiltered, and the ultrafiltration equipment is Merck Millipore's Labscale small ultrafilter (clamping two 50cm2 Pellicon XL membrane packages, cutoff 30KDa). The intermediate sample is concentrated to about 40-60mg / ml at a flow rate of 120-300L / m2·h and TMP is maintained at 0.6-1.5bar to obtain a concentrated sample.
[0170] Ultrafiltration replacement: The replacement buffer is 20mM sodium acetate-acetic acid buffer with a pH value of 5.5. A peristaltic pump is used to pump the sodium acetate-acetic acid buffer solution into the concentrated sample to obtain a mixed solution, and the mixed solution is further ultrafiltered while adjusting the pumping speed of the sodium acetate-acetic acid buffer solution to be consistent with the permeation flow rate, that is, keeping the weight of the sample constant. When the volume of the sodium acetate-acetic acid buffer solution is 7 times the weight of the concentrated sample, the replacement is completed to obtain an ultrafiltration replacement concentrate.
[0171] Secondary ultrafiltration concentration: sample and determine the protein concentration in the ultrafiltration replacement concentrate, calculate the theoretical volume of the ultrafiltration replacement concentrate at this time, add 1 / 9 of the theoretical volume of the amino acid additive mother solution of the ultrafiltration replacement concentrate, mix well, make the buffer system as shown in Table 2, and then use Merck Millipore's 30kDa ultrafiltration centrifuge tube to concentrate to the protein concentration of Table 2 to obtain a concentrated solution.
[0172] The obtained ultrafiltration concentrate was analyzed by SEC-HPLC to determine the active components in the sample. The determination method is as follows:
[0173] 1. Use high performance liquid chromatography (Agilent 1260 or equivalent instrument) and chromatographic columns (Waters, Specifications: 3.5μm, 7.8×300mm; or equivalent chromatographic column), mobile phase is PBS buffer;
[0174] 2. Unscrew the quaternary pump pipeline, flush the pipeline with 100% mobile phase at a flow rate of 5 ml / min for 3 minutes, tighten the quaternary pump switch, connect the chromatographic column, and flush the chromatographic column with 100% mobile phase at a flow rate of 1.0 ml / min for 30 minutes;
[0175] 3. Sample analysis method settings: flow rate is 1.0 ml / min, analysis time is 15 min, injection volume is 50 mg; detection wavelength is 280 nm; before injection, check the system adaptability (use reference material for continuous injection, the number of injections is not less than 5 times, and the last 5 results are calculated), then analyze 1 injection of blank sample, and then analyze the sample.
[0176] 4. Integrate the chromatographic peaks of each sample in the order of aggregates, main peaks and degradation products. All chromatographic peaks with retention times inconsistent with those of the blank sample should be integrated, and the proportion of each peak should be calculated by the area normalization method.
[0177] The results of determining the purity of QX009N in the ultrafiltration concentrated solution are shown in Table 2:
[0178] Table 2 Purity of QX009N in ultrafiltration concentrated solution
[0179]
[0180] From the results in Table 2, it can be seen that the monomer of QX009N is greater than 95%, the aggregate is less than 2%, and it basically does not contain host impurities.
[0181] The concentration of QX009N in the ultrafiltration concentrate was determined by ultraviolet spectrophotometry, and the determination method was as follows:
[0182] 1. Adjust the spectrophotometer wavelength to 280 nm and use blank buffer or water as a control to calibrate to zero.
[0183] 2. Dilute the sample with blank buffer or water, measure the absorbance of the sample at 280nm (the absorbance is guaranteed to be between 0.5-1.5), and calculate the sample concentration according to the following formula (the extinction coefficient of QX009N is 1.562)
[0184]
[0185] The viscosity of the solution was measured using a μVISC viscometer from Ruiosun, and the operating steps are as follows:
[0186] 1. Take a disposable special syringe, draw 200-400 microliters of the sample to be tested, remove all bubbles in the syringe, and gently wipe the remaining liquid with dust-free paper;
[0187] 2. Place the syringe in the tube groove and fix it. Click the instrument host interface to set the shear rate. After setting, click "Run" to test and record the viscosity value. Generally, the average value is taken after multiple measurements.
[0188] 3. For the detection of multiple samples, after the previous sample is tested, take out the syringe, empty the liquid in the tube, gently wipe the tube mouth with dust-free paper, and then proceed to the next sample absorption measurement.
[0189] The antibody concentration and viscosity of the concentrated solution were measured and the results are shown in Table 3:
[0190] Table 3 Summary of viscosity reduction results of different additives for anti-human IL-36R antibody
[0191]
[0192] It can be seen from the results in Table 3 that as the protein concentration increases, the viscosity value of the anti-human IL-36R antibody also increases. If no viscosity modifier is added, the viscosity value of the monoclonal antibody will reach 22.5cP at a concentration of 200mg / ml. Such a high viscosity value cannot be used to achieve the concentration process using a conventional ultrafiltration membrane. By adding a viscosity modifier (arginine hydrochloride, sodium chloride, sorbitol or a combination thereof), the antibody viscosity value under the same protein concentration condition can be reduced to less than 60% of the original, less than 15cP. Among them, the amino acid protective agent arginine hydrochloride can obtain a lower viscosity value due to its additional anti-aggregation effect. In summary, the subcutaneous injection concentration of the QX009N monoclonal antibody injection provided in this application can reach at least 150mg / mL.
[0193] Example 8 Preparation of a low viscosity liquid formulation containing high concentration of QX009N (HZD25-54)
[0194] The ultrafiltration concentrate was obtained by affinity chromatography, low pH inactivation, anion and cation exchange chromatography, tangential flow ultrafiltration concentration and other operations on the CHO cell fermentation broth expressing anti-human IL-36 monoclonal antibody. The concentration of QX009N in the ultrafiltration concentrate was determined to be approximately 150 mg / mL by ultraviolet spectrophotometry, and the viscosity of the ultrafiltration concentrate was determined to be 12.7 cP by the μVISC viscometer of Ruiosun. The ultrafiltration concentrate was filtered using a 0.2 μm filter membrane, and then mixed or replaced with amino acid protective agents of different concentrations, so that the buffer system and QX009N protein concentration of the sample are shown in Table 4, and the viscosity of the sample was determined by the same method as above. The specific preparation scheme and viscosity value results are shown in Table 4 below.
[0195] Table 4 Summary of viscosity reduction results of anti-human IL-36R antibody at different arginine hydrochloride concentrations
[0196]
[0197] It is generally believed that liquid preparations with a viscosity of less than 30 cP are suitable for subcutaneous injection. As shown in Table 4, by increasing arginine hydrochloride, the viscosity of the antibody under the same protein concentration condition can be reduced, and the subcutaneous injection concentration of QX009N (HZD25-54) can reach at least 120-160 mg / mL.
[0198] It should be understood that the scope of the present application is not intended to be limited to the exemplary aspects described above in the present application, but should include all currently known and future developed equivalents. In addition, it should be noted that, without departing from the technical principles of the present application, several improvements and modifications can also be made, and these improvements and modifications should also be regarded as the scope of the present application.
Claims
1. A liquid preparation comprising an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody, a viscosity modifier and a buffer salt, The concentration of the anti-human interleukin-36 receptor monoclonal antibody is 50 mg / mL or more, The viscosity modifier concentration is 10-500mM, The anti-human interleukin-36 receptor monoclonal antibody comprises three heavy chain complementary determining regions CDR-H1, CDR-H2 and CDR-H3 and three light chain complementary determining regions CDR-L1, CDR-L2 and CDR-L3, and, The amino acid sequence of the CDR-H1 is shown as NYAMG (SEQ ID NO: 1); The amino acid sequence of the CDR-H2 is shown as YISGGGSAYYASWAKG (SEQ ID NO: 2); The amino acid sequence of the CDR-H3 is shown as WAIKSYFFGMDL (SEQ ID NO: 3); The amino acid sequence of the CDR-L1 is shown as QASEYISSYLA (SEQ ID NO: 4); The amino acid sequence of the CDR-L2 is shown in QASTLAS (SEQ ID NO: 5); The amino acid sequence of the CDR-L3 is shown as QTNNAIHTYGGA (SEQ ID NO: 6).
2. The liquid preparation according to claim 1, in, The concentration of the anti-human interleukin 36 receptor monoclonal antibody is 50-300 mg / mL.
3. The liquid preparation according to claim 1, in, The concentration of the anti-human interleukin 36 receptor monoclonal antibody is 120-160 mg / mL.
4. The liquid preparation according to claim 1, in, The IL-36R monoclonal antibody comprises a heavy chain variable region and a light chain variable region, wherein The amino acid sequence of the heavy chain variable region is shown as EVQLVESGGGLVQPGGSLRLSCAASGIDLSNYAMGWVRQAPGKGLEWVGYISGGGSAYYASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWAIKSYFFGMDLWGQGTLVTVSS (SEQ ID NO: 7); The amino acid sequence of the light chain variable region is as follows: DIQMTQSPSSVSASVGDRVTITCQASEYISSYLAWYQQKPGKAPKLLIYQASTLASGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQTNNAIHTYGGAFGGGTKVEIK (SEQ ID NO: 8).
5. The liquid preparation according to any one of claims 1 to 4, in, The viscosity modifier is an amino acid protective agent.
6. The liquid preparation according to claim 5, in, The amino acid protective agent is arginine hydrochloride, histidine, lysine, methionine, proline or a combination thereof.
7. The liquid preparation according to claim 5, in, The amino acid protective agent is arginine hydrochloride.
8. The liquid preparation according to claim 7, in, The concentration of the arginine hydrochloride is 10-500 mM.
9. The liquid preparation according to claim 7, in, The concentration of the arginine hydrochloride is 40-200 mM.
10. The liquid preparation according to any one of claims 1 to 4, in, The viscosity modifier is sodium chloride.
11. The liquid preparation according to claim 10, in, The concentration of sodium chloride is 50-200 mM.
12. The liquid preparation according to any one of claims 1 to 4, in, The viscosity modifier is sucrose.
13. The liquid preparation according to claim 12, in, The concentration of the sucrose is 10-100 mg / mL.
14. The liquid preparation according to any one of claims 1 to 4, in, The viscosity modifier is sorbitol.
15. The liquid preparation according to claim 14, in, The concentration of sorbitol is 40-50 mg / mL.
16. The liquid preparation according to any one of claims 1 to 4, in, The buffer salt is sodium acetate, acetic acid or a combination thereof.
17. The liquid preparation according to any one of claims 1 to 4, in, The buffer salt concentration is 15-25 mM.
18. The liquid preparation according to any one of claims 1 to 4, in, The buffer salt concentration is 20 mM.
19. The liquid preparation according to any one of claims 1 to 4, in, The content of foreign proteins in the liquid preparation is less than 100 ppm.
20. The liquid preparation according to any one of claims 1 to 4, in, The pH of the liquid preparation is 5.0-6.
5.
21. The liquid preparation according to any one of claims 1 to 4, in, The viscosity of the liquid preparation is 10 cP or less.
22. Use of the liquid preparation according to any one of claims 1 to 21 in the preparation of a drug for treating IL-36R-mediated signal transduction-related diseases, in, The IL-36R-mediated signal transduction-related disease is selected from dermatitis, psoriasis or inflammatory bowel disease.
23. The use according to claim 22, in, The IL-36R-mediated signal transduction-related disease is selected from generalized pustular psoriasis, atopic dermatitis or inflammatory bowel disease.
Citation Information
Patent Citations
Synthetic antibody phage libraries
US20050079574A1
Synthetic antibody phage libraries
US20050119455A1
Variable domain library and uses
US20050266000A1
Multivalent antibodies and uses therefor
US20060025576A1
Methods of modifying eukaryotic cells
US20070061900A1
